About Us

Who We Are

UK Based

Camstent is a privately funded Cambridge, UK based company, and through its’ unique Bacteriaphobic® polymer coating technology is able to dramatically reduce biofilms on consumable silicon-based medical devices.

Reducing Biofilms

Reducing biofilms ensures reduction in infection-related issues which cause discomfort to patients, longer hospitalisation, increased usage of anti biotics and higher costs.

Addressing an Epidemic

Camstent is addressing a global hospital acquired infection (HAI) epidemic which severely affects patients and hospital economics. HAIs are estimated to cost global healthcare systems up to $10Bn per annum and a large proportion of these are due to urinary tract infections (UTI’s).

Our Devices

Camstent’s first proof of concept device is a coated Foley Catheter which is in clinical studies in the UK. Earlier studies have shown significant reduction in biofilms on the Camstent-coated catheter as compared to standard care uncoated catheter.

Meet Our Team

Mark Harwood

Chief Executive Officer (CEO)

Over 25 years in the Medical Device industry both in the private and public sectors.

Leadership of start-up’s, SME’s and Corporate companies in Europe, North America and Asia, including Arjo, Baxter Healthcare and PneumaCare.

Highly experienced in commercialisation of new medical technology, including FDA regulatory approval, brand expansion and global distribution.

Extensive experience in Mergers & Acquisitions.

Rahul Tiwari

Senior Scientist & PRRC

Dr. Rahul Tiwari is a Senior Scientist and PRRC at Camstent Ltd., specializing in polymer science. He holds a PhD in Natural Sciences from RWTH Aachen University, Germany and brings over 13 years of experience in the chemical industry. His work focuses on developing anti-microbial coatings for medical devices such as catheters, aiming to reduce hospital-acquired infections and enhance patient outcomes. Dr. Tiwari has a strong background in polymer and surface chemistry, polymer synthesis and characterization, as well as UV-curable coatings.

Prital Patel

Clinical Director

With over 14 years of experience in leading clinical trials across the pharmaceutical and medical device industries. With a proven track record in operational strategy, regulatory compliance, and cross-functional leadership, playing a central role in advancing innovative therapies and technologies from concept to market.

Overseeing the planning, execution, and delivery of clinical programs — ensuring timelines, budgets, and quality standards are met while maintaining a strong focus on patient safety and data integrity. Including regulatory submissions, site management &CRO oversight.

Alan Collins

Senior Principal Scientist

A global silicone industry specialist with more than 26 years’ experience covering technical and business roles in settings that included Europe, India and the Middle East. Worked in formulation development of silicone elastomers and in business development in areas such as textiles, engineering, personal care and healthcare.

Jason Howes

Regulatory Consultant

Experienced Medical Device Quality and Regulatory Affairs Specialist supporting worldwide market entry strategy, product approvals and ongoing compliance.

Stuart Norris

Quality & Regulatory Manager

Experienced Quality and Regulatory Affairs Manager with over 15 years of proven success in developing, implementing, and maintaining robust Quality Management Systems (QMS) to support ongoing product compliance and certification. A subject matter expert in global medical device regulations and standards—including ISO 13485, EU MDR, and FDA 21 CFR Part 820. Stuart is highly skilled in supporting regulatory submissions, leading audits, and ensuring continuous compliance throughout the product lifecycle.

Meet Our Key Opinion Leaders (KOLs)

Mr Mark Rochester

Clinical KOL

Mr Rochester was appointed as a Consultant Urologist at Norfolk and Norwich University Hospital in 2010 and was Clinical Director from 2016- 2024. He is now the Service Director for Theatres at NNUH and the deputy training programme director for urology in the East of England. He qualified from Cambridge University in 1998 with first class honours in medical sciences. After surgical training in Oxford, he undertook laboratory research which led to the post of Royal College of Surgeons of England Hunterian Professor in 2006. Mr Rochester has subspecialty trained in robotic kidney surgery and has trained many surgeons across the UK in this approach. He is also a recognised expert in benign prostate disease (BPH) and regularly teaches new surgical techniques to surgeons in the UK and across Europe. He is regularly invited to deliver lectures and training in BPH internationally and is actively involved currently in a number of trials for new BPH treatments as well as trials in kidney and prostate cancer.

Mr Maurizio Belci

Clinical KOL

Mr. Maurizio Belci is a Consultant in Rehabilitation Medicine with over 29 years of experience, specialising in spinal cord injuries and neurorehabilitation. Since 2011, he has served as a consultant at the National Spinal Injuries Centre (NSIC) at Stoke Mandeville Hospital, the UK’s pioneering spinal unit. Born in Croatia, Mr. Belci began his medical education at the University of Padua Medical School, graduating as a Doctor in Medicine & Surgery (DMS) in 1996. He obtained his Diploma from the Italian National Board of Medical and Surgical Examiners at Padova University in 1997. Subsequently, he moved to the UK, earning a Master’s in Surgical Science from Imperial College London in 2001. He was awarded Membership of the Royal College of Surgeons (MRCS) in 2006 and completed his Spinal Cord Injuries (Rehabilitation Medicine) training at Oxford in 2010. In 2016, he became a Fellow of the Royal College of Physicians, London. Throughout his career, Mr. Belci has held medical positions in Italy, Poland, Croatia, and across the UK, including roles at major hospitals in Torbay, Devon, Addenbrooke’s in Cambridge, and Preston, Lancashire, where he worked as a Senior House Officer in Neurosurgery. His clinical experience spans several specialties, including anaesthetics, obstetrics and gynaecology, trauma and orthopaedics, intensive care, and peripheral neuropathy. Mr. Belci has conducted extensive research in Spinal Cord Injury (SCI) on a variety of topics linked with the condition

Prof. Paul Williams

Academic KOL

Paul Williams is Emeritus Professor of Molecular Microbiology at the Biodiscovery Institute & School of Life Sciences, Faculty of Medicine & Health Sciences, University of Nottingham. He has served the University as Head of the School of Molecular Medical Sciences (2008-2013) and as Director of the Institute of Infection, Immunity & Inflammation (1996-2008). His research interests focus on the ways in which bacteria control virulence through cell-cell communication (quorum sensing) and the discovery of novel antibacterial agents and biofilm resistant polymers for preventing medical device associated infections. He has published over 400 research articles and patents and is listed in the 2025 Stanford Top 2% of cited scientists globally. He has served on the Medical Research Council Infection & Immunology board, BBSRC Plants and Microbes panel and on the scientific advisory board of the European Union Joint Programming Initiative in Antimicrobial Resistance. He was a Wellcome Trust Senior Investigator (2014-2022), Director of a Wellcome Trust Ph.D Training Programme in Antimicrobials and Antimicrobial Resistance (2016-2025) and is a member of the European Academy of Microbiology.

Prof. Morgan Alexander

Academic KOL

Morgan Alexander is Professor of Biomedical Surfaces in the School of Pharmacy at University of Nottingham. His research involves developing new biomaterials for application in healthcare whilst elucidating relationships between their surfaces and the biological response. Understanding these relationships is critical to the development of next generation biomaterials and it is the theme running through his work across a variety of areas spanning control of bacterial and fungal colonisation, immune response control by implants, stem engineering cell response with applications in medical devices and cell manufacture.

He led a Wellcome Trust funded team that discovered a novel class of bacterial biofilm resistance polymers that are applied on a CE marked catheter available for patients in the NHS. EPSRC has also supported large multidisciplinary projects led by Morgan into the discovery of materials chemistries and topographies which control immune cell response showing promise in wound care and implants. Morgan received a Clarivate Highly Cited Award in 2021, 2022 and 2023.